<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02077556</url>
  </required_header>
  <id_info>
    <org_study_id>201312011MINA</org_study_id>
    <nct_id>NCT02077556</nct_id>
  </id_info>
  <brief_title>Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients</brief_title>
  <official_title>The Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients, and the Effect of ABCB1、CYP3A4、CYP3A5、PORGenetic Polymorphism on the Two Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the effects of everolimus on tacrolimus
      pharmacokinetics (pk) in patients receiving de novo kidney transplants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multidrug immunosuppression regimens have synergistic effects which allow the use of lower
      doses of individual agents. These regimens generally include calcineurin inhibitors (CNIs:
      cyclosporine or tacrolimus), mammalian target of rapamycin (mTOR) inhibitors (everolimus or
      sirolimus), and corticosteroids. CNIs and mTOR inhibitors are substrates for cytochrome P450
      3A4 (CYP3A4) and P-glycoprotein (P-gp); in addition, cyclosporine is a inhibitor of CYP3A4
      and P-gp. Therefore, concomitant administration of those drugs may alter their serum levels.

      It is remained to be evaluated whether the pharmacokinetics or clinical efficacy of
      tacrolimus will be affected when the regimens contain everolimus in clinical practice and the
      effect of ABCB1、CYP3A4、CYP3A5、POR genetic polymorphism on the two Drugs. Mycophenolate
      mofetil (MMF) has no effect on pharmacokinetics of tacrolimus; therefore, MMF is used as a
      control to understand the effects of everolimus on pharmacokinetics of tacrolimus in patients
      receiving de novo kidney transplants. The effect of ABCB1、CYP3A4、CYP3A5、POR genetic
      polymorphism on the two Drugs was also assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profiles</measure>
    <time_frame>Post-operation day 8-10</time_frame>
    <description>Pharmacokinetic parameters include the maximum concentration, trough concentration, area under the whole-blood concentration-time curve between 0 and 12 hours, time to maximum concentration, volume of distribution at steady state, and clearance at steady state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute rejection</measure>
    <time_frame>Within the first 2 weeks post-transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Drug Interaction Potentiation</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus/Tacrolimus/Methylprednisolone &amp; Prednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mycophenolate mofetil/Tacrolimus/ Methylprednisolone &amp; Prednisolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus: 1 mg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 3-8 ng/mL</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Mycophenolate mofetil: 10-15 mg/kg orally every 12 hours from post-operation day 1 (decrease 50% dose if white blood cell &lt; 4000/mcL)</description>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL</description>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7</description>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually</description>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
    <other_name>Predonine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  De novo kidney transplants

          -  20 - 65 years old

          -  aspartate aminotransferase/alanine aminotransferase within 2 times the upper limit of
             normal range

        Exclusion criteria:

          -  Pregnancy

          -  Tuberculosis

          -  Hepatitis B or C carrier status

          -  Human immunodeficiency virus-positive status

          -  Retransplantation or multiorgan transplantation

          -  History of rheumatoid arthritis

          -  Use of drugs that might have enhanced or inhibited CYP3A4 or P-gp activity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meng-Kun Tsai</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fe-Lin Lin Wu</last_name>
    <phone>+886-2-3366 8784</phone>
    <email>flwu@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng-Kun Tsai</last_name>
      <phone>+886-972651461</phone>
      <email>mengkuntsai@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2014</study_first_submitted>
  <study_first_submitted_qc>March 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tacrolimus, everolimus, pharmacokinetics, drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

